Screening for metabolic bone diseases utilizing bone health screening panel
Location
Auditorium Pond Side
Start Date
26-2-2014 10:30 AM
Abstract
Background: Disturbances in mineral metabolism and bone disease are common, which if left unnoticed can lead to mineralization defects, fractures, nephrolithiasis and renal failure. Simultaneous biochemical testing with the several markers for bone health along with clinical history and examination improves the detection of a specific bone disorders and helps the physician in making important decisions. For this purpose a Bone Health Screening Panel was developed and an audit was conducted to determine its utility in identifying disorders of bone metabolism. Methods: An audit was conducted at section of Chemical Pathology, department of Pathology and Microbiology, Aga Khan University Hospital. Analysis was performed for biochemical parameters included in bone health screening panel done from January 2011 till November 2013. The low and high cut offs for all analytes were applied to assess the percentage of hypofunctioning and hyperfunctioning conditions.
Results: A total of 524 subjects underwent bone health profile testing over a period of 35 months. Majority was females (61%) and mean age of study subjects was 44.5 ± 17 years. Of them nearly 8% had kidney dysfunction. Most common bone mineral disorder observed in subjects with normal kidney function was Vitamin D deficiency. Overall 31% (n=163) subjects had high parathyroid hormone levels, of them 20 subject had primary hyperparathyroidism and rest had secondary hyperparathyroidism. Hypoparathyroidism was seen in 4.2% (n=22) subjects. In four subjects with hypomagnesemia, only one subject had hypoparathyroidism. Alkaline phosphatase was raised in 14.6% of subjects, of them osteomalacia was seen in only 15 subjects. Disorders of calcium and phosphate were also observed.
Conclusions: Bone health panel testing is useful in early diagnosis and management of metabolic bone disorders.
Keywords: Vitamin D deficiency (VDD), Primary Hyperparathyroidism, Hypermagnesemia, Hypercalcemia
Screening for metabolic bone diseases utilizing bone health screening panel
Auditorium Pond Side
Background: Disturbances in mineral metabolism and bone disease are common, which if left unnoticed can lead to mineralization defects, fractures, nephrolithiasis and renal failure. Simultaneous biochemical testing with the several markers for bone health along with clinical history and examination improves the detection of a specific bone disorders and helps the physician in making important decisions. For this purpose a Bone Health Screening Panel was developed and an audit was conducted to determine its utility in identifying disorders of bone metabolism. Methods: An audit was conducted at section of Chemical Pathology, department of Pathology and Microbiology, Aga Khan University Hospital. Analysis was performed for biochemical parameters included in bone health screening panel done from January 2011 till November 2013. The low and high cut offs for all analytes were applied to assess the percentage of hypofunctioning and hyperfunctioning conditions.
Results: A total of 524 subjects underwent bone health profile testing over a period of 35 months. Majority was females (61%) and mean age of study subjects was 44.5 ± 17 years. Of them nearly 8% had kidney dysfunction. Most common bone mineral disorder observed in subjects with normal kidney function was Vitamin D deficiency. Overall 31% (n=163) subjects had high parathyroid hormone levels, of them 20 subject had primary hyperparathyroidism and rest had secondary hyperparathyroidism. Hypoparathyroidism was seen in 4.2% (n=22) subjects. In four subjects with hypomagnesemia, only one subject had hypoparathyroidism. Alkaline phosphatase was raised in 14.6% of subjects, of them osteomalacia was seen in only 15 subjects. Disorders of calcium and phosphate were also observed.
Conclusions: Bone health panel testing is useful in early diagnosis and management of metabolic bone disorders.
Keywords: Vitamin D deficiency (VDD), Primary Hyperparathyroidism, Hypermagnesemia, Hypercalcemia